Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-854-4 | CAS number: 111-29-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Repeated dose toxicity:
- oral: NOAEL = 1000 mg/kg bw/day (OECD 422; 1,5-pentanediol CAS 111-29-5)
- oral: NOAEL = 1000 mg/kg bw/day (OECD 407; analogue 1,6-hexanediol CAS 629-11-8)
- oral: NOAEL = 400 mg/kg bw/day (OECD 408; analogue 1,6-hexanediol CAS 629-11-8)
- oral: NOAEL (systemic parental toxicity) = 1000 mg/kg bw/d (OECD 422; metabolite d-valerolactone CAS 542-28-9)
- oral: NOAEL (local parental toxicity)= 300 mg/kg bw/d (OECD 422; metabolite d-valerolactone CAS 542-28-9)
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Dose descriptor:
- NOAEL
- 400 mg/kg bw/day
Additional information
The evaluation of the endpoint repeated dose toxicity of 1,5-pentanediol (CAS 111-29-5) is based on a weight of evidence approach using the toxicological data of 1,5-pentanediol itself and the chemical analogue 1,6-hexanediol (CAS 629-11-8) and main metabolite of 1,5-pentanediol, d-valerolactone (CAS 542-28-9) (for WoE information, see chapter 13.2).
1,5-pentanediol:
In an OECD 422 study, male and female Wistar rats received 1,5-pentanediol at doses of 100, 300 or 1000 mg/kg/day by oral gavage administration. Males were treated daily for two weeks before pairing and up to necropsy (after a minimum of five consecutive weeks). Females were treated daily for two weeks before pairing, throughout pairing, gestation and until Day 13 of lactation. There was no adverse effect on body weight gain and there were no treatment-related findings at the hematological or biochemical examination of the blood. At the end of the treatment period, there were no treatment-related macroscopic or microscopic findings and there were no changes to organ weights. The no-observed-adverse-effect level (NOAEL) for systemic toxicity was therefore considered to be 1000 mg/kg/day.
1,6-Hexanediol:
Subacute toxicity study (oral, 28 days):
A repeated dose 28 -day oral toxicity study was conducted according OECD method 407 and EU method B.7. Five male and five female Wistar rats per dose received doses of 100, 400 and 1000 mg/kg/d 1,6-hexanediol (BASF, 1995). The only observable effects was a statistical significant decrease in body weight in females of the 400 mg/kg bw group and decreased body weight gain in female r.ats at the 400 and 1000 mg/kg/d dose level towards the end of the study, r)espectively. However, since no dose-response relationship was found, these effects were regarded as incidental. In parallel, the values for food consumption were also reduced, but without showing statistical significance. Furthermore, all reported changes were within ranges of historical controls. Thus, the NOEL was 1000 mg/kg bw/day under the condition of this study.
Subchronic toxicity study (oral, 90 days):
The effect of 1,6 -hexandiol on repeated dose toxicity was assessed in Wistar rats according to OECD 408 and GLP (BASF SE 2014). 1,6-Hexanediol was administered for 3 months daily by gavage to male and female Wistar animals at dose levels of 0, 100, 400 and 1000 mg/kg bw/d (test groups 0 - 3). Drinking water served as vehicle and vehicle control.
Regarding clinical examinations, the only effect observed was a treatment-related decrease of body weight inmale animals of test group 3 (1000 mg/kg bw/d)on study days 77, 84 and 91 compared to the control group (up to -10.5%). Body weight gain decreases were in males of test group 3 on study days 56, 63, 70, 77, 84 and 91 (up to -18.7%). No changes in body weight parameters were observed for male animals of test groups 1 and 2 (100 and 400 mg/kg bw/d). Furthermore, no treatment-related effects on body weight/body weight gain were observed in female animals of test groups 1-3 (100, 400 and 1000 mg/kg bw/d).
No treatment-related effects were observed on food and water consumption, FOB, and motor activity measurement.
Regarding clinical pathology,no treatment-related, adverse effects were observed up to a dose of the compound of 1000 mg/kg bw/d. Furthermore, there were no treatment-related effects in pathology as assessed by organ weight changes, gross lesions, and histopathological findings in male and female Wistar rats.
All findings occurred either individually or were biologically equally distributed over control and treatment groups. They were considered to be incidental or spontaneous in origin and without any relation to treatment.
The administration of 1,6 -Hexanediol by gavage to male and female Wistar rats for 3 months revealed a test substance-related decrease in body weight only in male animals at a dose level of 1000 mg/kg bw/d. No effects were noted in females receiving 1000 mg/kg bw/d, or at lower dose levels of either sex.
Therefore, under the conditions of the present study the no observed adverse effect level (NOAEL) was 400 mg/kg bw/d in male and 1000 mg/kg bw/d in female Wistar rats.
d-Valerolactone:
OECD 422, oral
d-Valerolactone was tested in a repeated dose/reproductive toxicity screening test (BASF SE, 2013, OECD 422). One local finding in the forestomach noted at 1000 mg/kg bw/d in a single female rat was the only local adverse effect observed after oral application. Therefore, a NOAEL for local parental toxicity of 300 mg/kg bw/d and a NOAEL for systemic parental toxicity of 1000 mg/kg bw/d was derived from this study.
Conclusion
Taking all available information into consideration, it can be concluded that 1,5-pentandiol, 1,6-hexanediol and d-valerolactone are of rather low systemic toxicity and do not induce excessive adverse effects at high doses (1000 mg/kg/d). Hence, classification is not warranted with respect to repeated dose toxicity. Considering the structural similarity of 1,5-pentanediol and 1,6-hexanediol and the in vivo metabolization to d-valerolactone, it can be concluded that 1,5-pentanediol does also not pose any risk to human health and does hence not require classification with respect to repeated dose toxicity.
Justification for classification or non-classification
The available information do not warrant classification of 1,5 -pentanediol with respect to repeated dose toxicity according to Regulation EC1272/2008 (CLP), respectively.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.